BPH 11. The revoLix 2 micron wave laser vaporesection for the treatment benign prostatic hyperplasia

Objective: To evaluate the safety and efficacy of the RevoLix 120W 2 micron continuous wave laser vaporesection in the treatment of benign prostatic hyperplasia (BPH).

Methods: We performed a retrospective chart review of 59 BPH patients who underwent RevoLix 120W 2 micron continuous wave laser vaporesection in our hospital from May 2010 to May 2011. The average age of these patients was 74 years (range, 68 years to 95 years). The operation duration, drop in hemoglobin, indwelling catheterization time, operation-associated complications, international prostatic symptom scores (IPSS), quality of life (QoL), urinary flow rate (Q_max), and post voiding residual urine volume (PVR) were recorded.

Results: All 59 patients recovered without any incident. The mean operative time was 58±23.2 min. Occasional venous hemorrhage occurred during the operation, but no arterial hemorrhage was observed. Hemoglobin decreased from preoperative 14.6 g/dL to postoperative 13.8 g/d (P<0.05). IPSS decreased from preoperative 20 ± 5.8 to postoperative 8±4.2 (P<0.05), QoL scores decreased from 4.8±0.8 to 2.2±0.9 (P<0.05), Q_max increased from 7.9±4.8 to 20.6±10.3 mL/sec (P<0.05), PVR decreased from 90.6±52.7 to 20.2±3.8 mL (P<0.05).

Conclusions: The RevoLix 120W 2-μm continuous wave laser vaporesection is safe and effective in the treatment of BPH.